Edgewise Therapeutics, Inc.

Report azionario NasdaqGS:EWTX

Capitalizzazione di mercato: US$5.2b

Edgewise Therapeutics Crescita futura

Criteri Future verificati 2/6

Edgewise Therapeutics prevede che gli utili e i ricavi cresceranno rispettivamente di 13.1% e 36.9% all'anno. Si prevede che l'EPS crescerà di 15.4% all'anno. Si prevede che il ritorno sul capitale proprio sarà di -7.6% in 3 anni.

Informazioni chiave

13.1%

Tasso di crescita degli utili

15.44%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili14.6%
Tasso di crescita dei ricavi36.9%
Rendimento futuro del capitale proprio-7.58%
Copertura analitica

Good

Ultimo aggiornamento09 Jul 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Seeking Alpha • Jun 05

Edgewise: 'Buy' On Muscular Dystrophy Program Sale And EDG-7500 Advancement

Summary Edgewise Therapeutics remains a "Buy," driven by pipeline focus and a transformative $2.65B sale of its muscular dystrophy program to Servier. Company will use the $1.55B upfront cash to fully fund EDG-7500 development for oHCM/nHCM, targeting pivotal phase 3 initiation in Q4 2026. Topline 12-week Part D data from the phase 2 CIRRUS-HCM study for EDG-7500 is expected in Q2 2026, a key catalyst for advancing to phase 3. A robust cash position extends the runway to a potential EDG-7500 approval, while EWTX pivots entirely to its cardiovascular pipeline and advances EDG-15400 for HFpEF. Read the full article on Seeking Alpha
Seeking Alpha • Mar 10

Edgewise Therapeutics: More Expensive Now, But Much More Derisked

Summary Edgewise Therapeutics' stock surged after strong midstage data from its Becker Muscular Dystrophy program, with the lead molecule sevasemten showing promising results. The GRAND CANYON trial, targeting Becker Muscular Dystrophy, aims for regulatory approval with primary endpoint NSAA, following positive Phase 2 CANYON data. Financially, Edgewise has a market cap of $2.67bn and a cash runway of 8-9 quarters, supporting ongoing and future trials. Despite the increased stock price, EWTX remains a buy due to its derisked status and potential success across multiple myosin inhibition programs. Read the full article on Seeking Alpha
Seeking Alpha • Dec 31

Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data

Summary Company achieved positive phase 2 CANYON study results for sevasemten in Becker Muscular Dystrophy, boosting long-term investment potential. Key catalysts include FDA and EMA meetings, GRAND CANYON study recruitment completion, and phase 2 CANYON data publication, all expected to likely enhance shareholder value. The pipeline extends beyond BMD, with sevasemten in phase 2 trials for Duchenne Muscular Dystrophy and EDG-7500 targeting Hypertrophic Cardiomyopathy, offering multiple growth opportunities. The global Becker Muscular Dystrophy market is expected to reach $1.28 billion by 2034. Read the full article on Seeking Alpha
Seeking Alpha • Sep 19

Edgewise: Stock Is Bouncing On Heart Disease Drug Data, Albeit From Just 7 Patients (Rating Upgrade)

Summary I previously rated Edgewise Therapeutics a sell due to limited market potential and lack of clinical data for sevasemten. Sevasemten, Edgewise's lead drug, remains unchanged in its potential, with ongoing pivotal studies for Becker Muscular Dystrophy. Edgewise stock has surged over 50% today however on Phase 1 data for EDG-7500, a cardiac sarcomere modulator for hypertrophic cardiomyopathy and diastolic dysfunction. The positive Phase 1 data for EDG-7500 significantly impacts Edgewise's valuation, highlighting the importance of considering early-stage assets. There is a long path to a potential approval shot, however, and the reliability of a 7-patient data set is not sufficient for a "buy" recommendation at this time. One for the watchlist. Read the full article on Seeking Alpha
Seeking Alpha • Aug 05

Edgewise Therapeutics: Strong Open Label Data Makes For A Bullish Signal

Summary Edgewise Therapeutics develops small molecules for myopathies, with lead molecule sevasemten in phase 3 for Becker Muscular Dystrophy. Company was founded in 2017, backed by OrbiMed, with an experienced management team and strong financials. Sevasemten offers a genotype-agnostic approach, competitive difference from dystrophin-targeting therapies, with potential high market valuation. Read the full article on Seeking Alpha
Seeking Alpha • May 10

Edgewise: Intriguing Drug Candidate, But Consider Selling After Recent Run

Summary Edgewise Therapeutics, Inc. reported its first quarter earnings, revealing a strong cash position of $532m and a net loss of $(28.5m). The company is advancing two clinical-stage programs, including a pivotal trial for Becker muscular dystrophy and a Phase 1 trial for hypertrophic cardiomyopathy for a second candidate. Sevasemten, the lead drug candidate, showed positive results in a two-year study for Becker muscular dystrophy, supporting the hypothesis that it can preserve and improve muscle function. An FDA Fast Track designation for sevasemten has triggered a bull run that has seen the share price gain by >250%. A lack of genuinely meaningful catalysts in 2024, and a lengthy wait until an application for approval can be made, make this a good time to sell, in my view, although long-term, there are signs the drug is approvable. Read the full article on Seeking Alpha
Seeking Alpha • Feb 18

Edgewise Therapeutics: Behind The Massive Rally

Summary Edgewise Therapeutics' stock has rallied massively after receiving FDA designations for its lead asset, EDG-5506, which has a potential $750 million opportunity in BMD. The company is focused on developing precision medicines for severe genetic neuromuscular and cardiac disorders. Edgewise Therapeutics has recently raised additional capital and has four data readouts for EDG-5506 scheduled for 2024. A full investment analysis around Edgewise Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Sep 13

Edgewise Therapeutics proposes $100M stock offering plan

Edgewise Therapeutics (NASDAQ:EWTX) announced Tuesday its plans to raise $100M in the underwritten public stock offering; price, size and other terms not yet determined. The Colorado-based biopharmaceutical company told underwriters will be granted an overallotment option to purchase up to an additional $15M shares. It comes right after Edgewise Therapeutics received FDA's approval for phase 2 trial of its experimental drug, EDG-5506, in children with muscular dystrophy. Stock is down 2% in pre-market trading.

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:EWTX - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/202858-190N/A-1689
12/31/202747-174-68-749
12/31/2026209-207-4432018
3/31/2026N/A-176-149-148N/A
12/31/2025N/A-168-144-144N/A
9/30/2025N/A-157-133-132N/A
6/30/2025N/A-151-126-125N/A
3/31/2025N/A-146-119-118N/A
12/31/2024N/A-134-110-109N/A
9/30/2024N/A-124-110-109N/A
6/30/2024N/A-116-105-104N/A
3/31/2024N/A-106-99-98N/A
12/31/2023N/A-100-98-92N/A
9/30/2023N/A-89-86-77N/A
6/30/2023N/A-81-77-67N/A
3/31/2023N/A-76-72-63N/A
12/31/2022N/A-68-58-53N/A
9/30/2022N/A-61-53-50N/A
6/30/2022N/A-56-48-46N/A
3/31/2022N/A-51-41-40N/A
12/31/2021N/A-43-34-34N/A
9/30/2021N/A-36-29-29N/A
6/30/2021N/A-27-24-24N/A
3/31/2021N/A-21-18-18N/A
12/31/2020N/A-17-15-15N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che EWTX rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che EWTX rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che EWTX rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di EWTX ( 36.9% all'anno) crescerà più rapidamente del mercato US ( 13% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di EWTX ( 36.9% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che EWTX non sarà più redditizia tra 3 anni.

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/07/10 17:15
Prezzo dell'azione a fine giornata2026/07/10 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Edgewise Therapeutics, Inc. è coperta da 15 analisti. 9 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Cory KasimovEvercore ISI
Paul ChoiGoldman Sachs
Debjit ChattopadhyayGuggenheim Securities, LLC